These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 18794128)
1. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Guo W; Wu S; Liu J; Fang B Cancer Res; 2008 Sep; 68(18):7403-8. PubMed ID: 18794128 [TBL] [Abstract][Full Text] [Related]
2. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Guo W; Wu S; Wang L; Wang RY; Wei X; Liu J; Fang B Mol Cancer Ther; 2009 Feb; 8(2):441-8. PubMed ID: 19208825 [TBL] [Abstract][Full Text] [Related]
3. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. Guo W; Wu S; Wang L; Wei X; Liu X; Wang J; Lu Z; Hollingshead M; Fang B PLoS One; 2011; 6(12):e28487. PubMed ID: 22174819 [TBL] [Abstract][Full Text] [Related]
5. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237 [TBL] [Abstract][Full Text] [Related]
6. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987 [TBL] [Abstract][Full Text] [Related]
7. Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Linch M; Sanz-Garcia M; Rosse C; Riou P; Peel N; Madsen CD; Sahai E; Downward J; Khwaja A; Dillon C; Roffey J; Cameron AJ; Parker PJ Carcinogenesis; 2014 Feb; 35(2):396-406. PubMed ID: 24072773 [TBL] [Abstract][Full Text] [Related]
8. The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer. Luo Q; Tang L; Lin H; Huang J; Zhang T; Liu Y; Wang J; Zhan P; Yin X; Su X; Ji Q; Yu D; Xu L Lung Cancer; 2014 May; 84(2):190-5. PubMed ID: 24636699 [TBL] [Abstract][Full Text] [Related]
9. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680 [TBL] [Abstract][Full Text] [Related]
10. Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. Murray NR; Jamieson L; Yu W; Zhang J; Gökmen-Polar Y; Sier D; Anastasiadis P; Gatalica Z; Thompson EA; Fields AP J Cell Biol; 2004 Mar; 164(6):797-802. PubMed ID: 15024028 [TBL] [Abstract][Full Text] [Related]
11. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Regala RP; Weems C; Jamieson L; Khoor A; Edell ES; Lohse CM; Fields AP Cancer Res; 2005 Oct; 65(19):8905-11. PubMed ID: 16204062 [TBL] [Abstract][Full Text] [Related]
12. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Regala RP; Thompson EA; Fields AP Cancer Res; 2008 Jul; 68(14):5888-95. PubMed ID: 18632643 [TBL] [Abstract][Full Text] [Related]
13. Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis. Yang J; Wang J; Zhang H; Li C; Chen C; Zhu T Carcinogenesis; 2021 Apr; 42(3):344-356. PubMed ID: 33146712 [TBL] [Abstract][Full Text] [Related]
14. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669 [TBL] [Abstract][Full Text] [Related]
15. Atypical protein kinase Cι (PKCι) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKCι-SKP2-AKT pathway. Liu SG; Wang BS; Jiang YY; Zhang TT; Shi ZZ; Yang Y; Yang YL; Wang XC; Lin DC; Zhang Y; Yang H; Cai Y; Zhan QM; Wang MR Mol Cancer Res; 2011 Apr; 9(4):390-402. PubMed ID: 21310827 [TBL] [Abstract][Full Text] [Related]
16. K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin. Ma Y; Guo FC; Wang W; Shi HS; Li D; Wang YS Mol Med Rep; 2013 Sep; 8(3):763-8. PubMed ID: 23877793 [TBL] [Abstract][Full Text] [Related]
17. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through ERK, Akt and survivin in pancreatic cancer cells. Rabi T; Venkatanarashiman M Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674 [TBL] [Abstract][Full Text] [Related]
18. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929 [TBL] [Abstract][Full Text] [Related]
19. Survival function of protein kinase C{iota} as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated bad kinase. Jin Z; Xin M; Deng X J Biol Chem; 2005 Apr; 280(16):16045-52. PubMed ID: 15705582 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma. Kim KH; Chung C; Kim JM; Lee D; Cho SY; Lee TH; Cho HJ; Yeo MK BMC Cancer; 2019 Aug; 19(1):804. PubMed ID: 31412817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]